Results 241 to 250 of about 752,763 (369)
Disrupting CSPG‐Driven Microglia–Astrocyte Crosstalk Enables Scar‐Free Repair in Spinal Cord Injury
This study identifies CSPGs as key drivers of glial scar maturation after spinal cord injury by reprogramming microglial metabolism and inducing astrocyte fibrosis. To address this, a reactive oxygen species‐responsive, reactive astrocyte‐targeted ChABC gene delivery system is designed to locally degrade CSPGs, precisely disrupt maladaptive glial ...
Yufei Zheng +10 more
wiley +1 more source
Rosai Dorfman Disease: A Myriad of Presentations-Multisystem Involvement Including Bone Marrow. [PDF]
Susai Manickam DJ +3 more
europepmc +1 more source
Nanozyme‐Integrated Hydrogel Targeting AGEs for Diabetic Osteoarthritis Therapy
A nanozyme–integrated hydrogel (PTC‐MP) exhibiting with mild photothermal effects is constructed, and a “3R” (restrain‐restore‐reinforce) strategy is proposed for diabetic osteoarthritis (DOA) treatment based on advanced glycation end products (AGEs) targeting.
Rui Chen +8 more
wiley +1 more source
Post-COVID-19 subacute painless thyroiditis: a case report in an anabolic androgenic steroid user. [PDF]
Skrzypiec-Spring M +3 more
europepmc +1 more source
Skull base aspergillosis in an immunocompetent elderly man with early response to steroid
Pamela Sarkar +3 more
openalex +2 more sources
Repurposing of Chemokine Antagonists for Combined Phase‐Resolved Spinal Cord Injury Treatment
Spinal cord injury (SCI) in mammals is accompanied by a massive cytokine storm in cerebrospinal fluid, mainly driven by CXCL1, IL‐6, and CCL2‐5. Sub‐acute phase is mostly associated with IL‐2, IL‐7, CCL22, and CX3CL1, whereas TNFα and IL17α permanently persists in CNS even weeks following SCI.
Alexey A. Belogurov Jr. +20 more
wiley +1 more source
Nivolumab-Induced Hemophagocytic Lymphohistiocytosis (HLH) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. [PDF]
Virdi RK, Hussain U, Bitran J.
europepmc +1 more source
The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen +5 more
wiley +1 more source

